cisplatin + docetaxel + sunitinib

This is a combination regimen consisting of three drugs—cisplatin, docetaxel, and sunitinib—used primarily in the treatment of advanced solid tumors such as non-small cell lung cancer (NSCLC). - **Cisplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Docetaxel** is a taxane-class chemotherapeutic that stabilizes microtubules and inhibits cell division. - **Sunitinib** is an oral small molecule multi-targeted tyrosine kinase inhibitor (TKI) with antiangiogenic and antitumor activity; it targets receptors including VEGFR, PDGFR, KIT, FLT3, CSF1R, and RET. The combination aims to enhance antitumor efficacy by combining cytotoxic chemotherapy (cisplatin + docetaxel) with targeted antiangiogenic therapy (sunitinib). Clinical studies have evaluated this regimen for safety and efficacy in NSCLC patients who had not responded to prior therapies. The combination has shown promising response rates with manageable toxicity profiles when doses are adjusted appropriately[1][2].